ストックスクリーナーアプリを入手
20.54
2.65%
-0.56
アフターアワーズ：
20.45
-0.09
-0.44%
Seaport Therapeutics Inc (SPTX) 最新ニュース
Seaport Therapeutics, Inc. Revenue Breakdown – BOATS:SPTX - TradingView
Lana Gladstein Net Worth (2026) - GuruFocus
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
Enterprise value to EBITDA forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Q2 Earnings Forecast for SPTX Issued By HC Wainwright - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Rating Upgraded by HC Wainwright - MarketBeat
Seaport Therapeutics stock initiated at buy by H.C. Wainwright - Investing.com Canada
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - AOL.com
Wolfe Research Initiates Seaport Therapeutics(SPTX.US) With Hold Rating - Moomoo
Price to earnings forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Price to sales forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SPTX Forecast — Price Target — Prediction for 2027 - TradingView
Seaport Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPTX) - TradingView
Price to book forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Enterprise value to EBIT forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Insider Stock Purchases: June 24, 2026 - Moomoo
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
PureTech-founded Seaport Therapeutics advances anxiety drug after positive Phase 1 data - grafa.com
J.P. Morgan Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
PureTech-founded Seaport reports positive GlyphAgo phase 1 data - marketscreener.com
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target By Investing.com - Investing.com Nigeria
New oral anxiety drug aims to cut liver tests after early trial - Stock Titan
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target - Investing.com India
PureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC) - Yahoo Finance UK
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgotm in Healthy Volunteers - Lelezard
Seaport Therapeutics reports positive phase 1 data for GlyphAgo By Investing.com - Investing.com Nigeria
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Positive Trial Results for Seaport Therapeutics (SPTX) in Anxiet - GuruFocus
Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
Seaport Pops on Q1 Numbers - Baystreet.ca
Seaport Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Seaport Therapeutics Reports Strong Q1 2026 Results, Advances Neuropsychiatric Drug Pipeline, and Raises $260M in IPO - Minichart
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):